Tuberculosis
Presents Major Challenges to HIV Treatment in Developing Countries
On
a global scale, tuberculosis
(TB) is among the leading causes of morbidity and mortality among people
with HIV. This problem has become a greater concern in recent years with the
spread of multidrug-resistant TB (MDR-TB) and the emergence of extensively drug-resistant
TB (XDR-TB). In
the July 23/30 issue of the Journal of the American Medical Association (JAMA),
Diane Havlir, MD, of the University of California at San Francisco and colleagues
looked at the challenges TB coinfection presents for the HIV care and treatment
in resource-limited countries. Tuberculosis
poses a risk throughout the course of HIV disease, even after successful initiation
of antiretroviral therapy. "HIV
programs designed for longitudinal care are ideally suited to implement TB control
measures and have no option but to address TB vigorously to save patient lives,
to safeguard the massive investment in HIV treatment, and to curb the global TB
burden," they wrote.
The
authors proposed a "framework of strategic actions" for HIV care programs
to optimally integrate TB into their services. The core activities of this framework,
they wrote, "include intensified TB case finding, treatment of TB, isoniazid
preventive treatment, infection control, administration of ART, TB recording and
reporting, and joint efforts of HIV and TB programs at the national and local
levels." Below
is a media release from JAMA summarizing the article: Tuberculosis
Presents Major Challenges to HIV Treatment in Developing Countries CHICAGO
- Human immunodeficiency virus (HIV) care and treatment programs in resource-limited
settings must aggressively address tuberculosis (TB) and the emerging multidrug-resistant
TB epidemic to save patient lives and to curb the global TB burden, a major cause
of death for persons with HIV, according to an article in the July 23/30 issue
of JAMA.
Tuberculosis is a threat throughout the course of HIV disease.
"As HIV care expands further, there is both an opportunity and necessity
for incorporation of TB control activities into these programs. Tuberculosis programs
simply do not have the capacity to provide ongoing TB screening, prevention, and
treatment for millions of individuals receiving HIV care," the authors write.
Diane V. Havlir, MD, of the University of California, San Francisco, and
colleagues examined interactions between HIV and TB for HIV care programs and
the framework for HIV programs to incorporate TB activities, and global progress
in implementation.
The authors write that TB poses numerous challenges,
including drug-resistance; difficulty in diagnosis and treatment in HIV-infected
persons; and complications from drug interactions. "Finding and treating
TB cases, administering antiretroviral therapy (ART) and isoniazid preventive
therapy [IPT; an antibacterial drug], and infection control are critical activities
to incorporate into HIV care programs, the first chronic care models to emerge
in many developing countries. Because patients with HIV are at risk for TB throughout
life, activities should be ongoing in pediatric and adult ART clinics, pre-ART
clinics (keeping relatively healthy patients engaged in care), and maternal health
programs."
The authors propose several strategic approaches to reduce
TB burden for HIV care and treatment programs. They include:
TB Intensified
Case Finding -- Finding and treating TB promptly is the most effective TB control
measure. Intensified case finding includes both active identification of TB among
patients with HIV in care and screening their household members for active TB.
Treating Individuals
With Active TB -- The authors propose expansion of a care model whereby TB is
treated by HIV programs. HIV care staff are trained to diagnose and treat a wide
array of infections associated with HIV disease. "Tuberculosis should be
no exception."
Isoniazid Preventive
Therapy -- HIV programs may need to work with country policymakers to permit IPT
administration, which in some countries is either against national policy or impossible
because of the stringent requirements for the exclusion of TB before IPT initiation.
Antiretroviral
Therapy -- ART is one of the most powerful weapons against TB. From the perspective
of TB prevention, the earlier that ART is initiated, the less the risk for TB.
TB Infection
Control -- One of the most challenging areas in TB infection control is the implementation
of measures in both outpatient and inpatient health care facilities that will
reduce the risk of TB transmission and protect health care workers. Tuberculosis
infection control guidelines exist but are rarely implemented.
TB Recording
and Reporting -- It is essential that HIV care programs adhere to TB reporting
requirements. Standardized recording and reporting formats in accordance with
national TB and AIDS control guidelines should be used.
Joint HIV/TB
Planning -- The successful implementation of TB interventions in HIV services
requires effective communication, coordination, and collaboration with TB control
programs.
"HIV
care programs must take a bold approach to TB prevention, diagnosis, and treatment
to successfully address the catastrophic and intersecting epidemics of HIV and
TB. HIV programs need to take advantage of new earmarked funds for HIV/TB activities
from agencies such as PEPFAR and the Global Fund to Fight HIV, TB, and Malaria.
They must push for access for rapid TB diagnostic tests, conduct operational research,
and launch educational efforts in partnership with the community to reduce TB
transmission. Shortages in the health care workforce and laboratory capabilities
clearly represent the greatest obstacles. However, the possibility for progress
has never been greater with the global commitment to health care infrastructure
strengthening geared toward consolidating the momentum through disease-specific
efforts such as HIV and TB," the authors conclude.
|
7/25/08 Sources DV
Havlir, H Getahun, I Sanne, and others. Opportunities
and challenges for HIV care in overlapping HIV and TB epidemics. Journal
of the American Medical Association 300(4): 423-430. July 23/30, 2008.
Tuberculosis
Presents Major Challenges to HIV Treatment in Developing Countries. Media Release.
July 22, 2008.
|